Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations

被引：0
|
作者：
Geng, R. [1 ]
Chen, Y. [1 ]
Miao, J. [2 ]
Liu, H. [1 ]
Qin, Y. [1 ]
Han, Z. [1 ]
Li, S. [1 ]
Guan, Y. [2 ]
Wu, H. [3 ]
Zhao, Y. [2 ]
Wang, Y. [1 ]
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Beijing Chao Yang Hosp, Beijing, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Furmonertinib; Stage I NSCLC; Adjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA15.13
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [31] High-risk surgically resected pediatric melanoma and adjuvant interferon therapy
    Chao, MM
    Schwartz, JL
    Wechsler, DS
    Thornburg, CD
    Griffith, KA
    Williams, JA
    PEDIATRIC BLOOD & CANCER, 2005, 44 (05) : 441 - 448
  • [32] ADJUVANT CISPLATINUM-DOCETAXEL CHEMOTHERAPY IN STAGE IB-II RESECTED NSCLC PATIENTS: THE TOLEDO TRIAL
    Bosquee, L.
    Germonprez, P.
    Aerts, J.
    Peters, F.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S52 - S53
  • [33] Role of adjuvant chemotherapy in patients with pathological stage I NSCLC with high-risk features.
    Arjyal, Lubina
    Uprety, Dipesh
    Frankki, Susan M.
    Borgert, Andrew J.
    Marinier, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Quah, Hak-Mien
    Chou, Joanne F.
    Gonen, Mithat
    Shia, Jinru
    Schrag, Deborah
    Landmann, Ron G.
    Guillem, Jose G.
    Paty, Philip B.
    Temple, Larissa K.
    Wong, W. Douglas
    Weiser, Martin R.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 503 - 507
  • [35] MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
    Therasse, P.
    Vansteenkiste, J. F.
    Zielinski, M.
    De Pas, T. M.
    Atanackovic, D.
    Sequist, L. V.
    Vallieres, E.
    Swisher, S.
    Adams, S.
    Passlick, B.
    Eberhardt, W. E. E.
    Grunenwald, D.
    Mok, T.
    Boyer, M.
    Katz, A.
    Douillard, J.
    Debois, M.
    Brichard, V. G.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis
    Zhao, Ke
    Yang, Libing
    Liu, Lei
    Wang, Guige
    Zhang, Jiaqi
    Gao, Xuehan
    Guo, Chao
    Huang, Cheng
    Chen, Yeye
    Li, Shanqing
    BMC SURGERY, 2024, 24 (01)
  • [37] Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)
    Han, B.
    Fang, W.
    Chen, C.
    Zhang, W.
    Zhang, B.
    Yao, F.
    Shi, J.
    Yue, D.
    Qi, Y.
    Zhu, Z.
    Xie, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S287 - S287
  • [38] Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies
    Gill, Sharlene
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2014, 35 (03) : 197 - 202
  • [39] Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR
    Dao, T. V.
    Soo, R. A.
    Batra, U.
    Tamayo, M. B. E.
    Tejado Gallegos, L. F.
    Donner, N.
    Alsayed, M.
    Huggenberger, R.
    Reungwetwattana, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S271 - S271
  • [40] Assessment of adjuvant therapy in resected head and neck cancer with high-risk features
    Ajmani, Gaurav S.
    Nocon, Cheryl C.
    Wang, Chi-Hsiung
    Bhayani, Mihir K.
    ORAL ONCOLOGY, 2017, 74 : 15 - 20
12345